Stockreport

OCU410's Phase 2 Gene-Agnostic Results in Dry AMD Might Change The Case For Investing In Ocugen (OCGN) [Yahoo! Finance]

Ocugen, Inc.  (OCGN) 
PDF degeneration, showing a 46% reduction in macular lesion growth at 12 months for medium and high doses versus control and no therapy-related serious adverse events across [Read more]